XYLOCAINE INJECTION 1% (5ML)

Valsts: Singapūra

Valoda: angļu

Klimata pārmaiņas: HSA (Health Sciences Authority)

Aktīvā sastāvdaļa:

LIGNOCAINE HCl ANHYDROUS

Pieejams no:

DCH AURIGA SINGAPORE

ATĶ kods:

N01BB02

Deva:

50 mg/5 ml

Zāļu forma:

INJECTION

Kompozīcija:

LIGNOCAINE HCl ANHYDROUS 50 mg/5 ml

Ievadīšanas:

EPIDURAL, SUBARACHNOID, INFILTRATION

Receptes veids:

Prescription Only

Ražojis:

ASTRAZENECA PTY LTD

Autorizācija statuss:

ACTIVE

Autorizācija datums:

1991-04-05

Lietošanas instrukcija

NAME OF DRUG
The active ingredient in XYLOCAINE is lignocaine hydrochloride.
The CAS number for lignocaine hydrochloride, monohydrate is 6108-05-0.
The chemical name for lignocaine hydrochloride is
2-Diethylaminoaceto-2’6’-xylidide.
The Australian Approved Name is lignocaine hydrochloride.
The chemical structure of lignocaine is:
DESCRIPTION
Lignocaine is classed as a membrane stabilising agent and is a local
anaesthetic of the amide
type. It is extremely stable and can be sterilised by autoclaving,
repeated a maximum of two
times if necessary.
Plain aqueous solutions are sterile, isotonic and contain lignocaine
hydrochloride, sodium
chloride, sodium hydroxide for pH adjustment and water for injections.
XYLOCAINE solutions
contain no antimicrobial agent and should be used only once and any
residue discarded.
Plain aqueous solutions of lignocaine hydrochloride have a pH of
5.0-7.0 (approx.). Lignocaine
base has a pKa of 7.85 (25°C), an oil/water coefficient of 2.9 and a
molecular weight of 234.3.
PHARMACOLOGY
Lignocaine, like other local anaesthetics, causes a reversible
blockade of impulse propagation
along nerve fibres by preventing the inward movement of sodium ions
through the nerve
membrane. Local anaesthetics of the amide type are thought to act
within the sodium channels
of the nerve membrane.
Local anaesthetic drugs may have similar effects on excitable
membranes in the brain and
myocardium. If excessive amounts of drug reach the systemic
circulation rapidly, symptoms
and signs of toxicity will appear, emanating mainly from the central
nervous system and
cardiovascular systems.
Central nervous system toxicity usually precedes the cardiovascular
effects as it occurs at
lower plasma concentrations. Direct effects of local anaesthetics on
the heart include slow
conduction, negative inotropism and eventually cardiac arrest.
Indirect cardiovascular effects, e.g. hypotension and bradycardia, may
occur after epidural or
spinal administration depending on the extent of the concomitant
sympathetic block.
Pharm

Produkta apraksts

XYLOCAINE INJECTION 1% (5 ML)
Lignocaine Hydrochloride
PRODUCT INFORMATION
Injection solution for the production of local or regional anaesthesia
NAME OF DRUG
The active ingredient in XYLOCAINE is lignocaine hydrochloride.
The CAS number for lignocaine hydrochloride, monohydrate is 6108-05-0.
The chemical name for lignocaine hydrochloride is
2-Diethylaminoaceto-2’6’-xylidide.
The Australian Approved Name is Lidocaine (lignocaine hydrochloride.
The chemical structure of lignocaine is:
DESCRIPTION
Lignocaine is classed as a membrane stabilising agent and is a local
anaesthetic of the amide type. It is extremely stable and can be
sterilised by
autoclaving, repeated a maximum of two times if necessary.
Plain aqueous solutions are sterile, isotonic and contain lignocaine
hydrochloride, sodium
chloride, sodium hydroxide for pH adjustment and
water for injections. XYLOCAINE solutions contain no antimicrobial
agent and should be used only once and any residue discarded.
Plain aqueous solutions of lignocaine hydrochloride have a pH of
5.0-7.0 (approx.). Lignocaine
base has a pKa of 7.85 (25°C), an oil/water
coefficient of 2.9 and a molecular weight of 234.3.
PHARMACOLOGY
Lignocaine, like other local anaesthetics, causes a reversible
blockade of impulse propagation
along nerve fibres by preventing the inward
movement of sodium ions through the nerve membrane. Local anaesthetics
of the amide type are thought to act within the sodium channels of the
nerve membrane.
Local anaesthetic drugs may have similar effects on excitable
membranes in the brain and myocardium. If excessive amounts of drug
reach the
systemic circulation rapidly, symptoms and signs of toxicity will
appear, emanating mainly from the central nervous system and
cardiovascular
systems.
Central nervous system toxicity usually precedes the cardiovascular
effects as it occurs at
lower plasma concentrations. Direct effects of local
anaesthetics on the heart include slow conduction, negative inotropism
and eventually cardiac arrest.
Indirect cardiovascular eff